Screener
Ultragenyx Pharmaceutical RARE Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockValue.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.001 per share—25.0 shares authorized; nil outstanding in 2026 and in 2025 | — | — |
| Common stock, par value of $0.001 per share—250.0 shares authorized; outstanding—98.6 in 2026 and 96.6 in 2025 | — | — |
| Treasury stock, at cost, 0.3 shares in 2026 and 0.2 shares in 2025 | (10) | (8) |
| Deferred compensation obligation | 10 | 8 |
| Additional paid-in capital | 4,518 | 4,451 |
| Accumulated other comprehensive income | — | 1 |
| Accumulated deficit | (4,809) | (4,532) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's treasury stock?
- Ultragenyx Pharmaceutical (RARE) reported treasury stock of $10M in Q2 2026.
- How has Ultragenyx Pharmaceutical's treasury stock changed year-over-year?
- Ultragenyx Pharmaceutical's treasury stock increased by 25.1% year-over-year, from $7.99M to $10M.
- What does treasury stock mean?
- Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.
Ask your AI about Ultragenyx Pharmaceutical's treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude